BioSpace News Archive

BioVaxys Technology Corp. is pleased to announce that it has closed the first tranche of its previously announced non-brokered private placement.

The diagnostic company SphingoTec GmbH announces the introduction of novel biomarker penKid in the clinical routine management of patients on a test basis in a total of four units at the University Hospital Heidelberg and Heidelberg Kidney Center.

89bio, Inc. announced the presentation of data from ENTRIGUE, its Phase 2 proof-of-concept trial of pegozafermin in severe hypertriglyceridemia at the European Society of Cardiology Congress 2022.

Nanoscope Therapeutics Inc. today announced that Aaron Osborne , Chief Medical Officer, will give a presentation on clinical development of Nanoscope’s Multi-Characteristic Opsin (MCO) gene therapy platform.

Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the third quarter of 2022.

This week, the Association of Clinical Research Organizations (ACRO)’s Diversity and Inclusion in Clinical Trials committee is proud to share ACRO’s Diversity, Equity, and Inclusion Principles Statement.

Todos Medical, Ltd. today announced that its Atlanta-area CLIA/CAP-certified clinical laboratory Provista Diagnostics, Inc. is now offering saliva-only MonkeyPox testing.

Vivos Therapeutics, Inc. (NASDAQ: VVOS) (“Vivos” or the “Company”) today announced that it has received a notice (“Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that it was not in compliance with requirements of Nasdaq Listing Rule 5250(c)(1) as a result of not having timely filed its Quarterly Report on Form 10-Q for the quarter ended June 30, 2022 (the “Form 10-Q”).

Kira Pharmaceuticals, a global biotechnology company pioneering transformational complement therapies to treat immune-mediated diseases, will present preclinical data supporting its bifunctional approach to complement inhibition at the 2022 European Meeting on Complement in Human Disease (EMCHD) Conference.

Timber Pharmaceuticals, Inc. announced that results from the previously completed Phase 2b CONTROL study that evaluated TMB-001, a topical isotretinoin formulated using the Company’s patented IPEG™ delivery system, in moderate to severe congenital ichthyosis (CI) are published in the Journal of the American Academy of Dermatology.